

Rapid Report

Exercise increases Ca²⁺–calmodulin-dependent protein kinase II activity in human skeletal muscle

Adam J. Rose and Mark Hargreaves

Centre for Physical Activity and Nutrition, School of Health Sciences, Deakin University, Burwood, Australia 3125

There is evidence in rodents that Ca²⁺–calmodulin-dependent protein kinase II (CaMKII) activity is higher in contracting skeletal muscle, and this kinase may regulate skeletal muscle function and metabolism during exercise. To investigate the effect of exercise on CaMKII in human skeletal muscle, healthy men ($n = 8$) performed cycle ergometer exercise for 40 min at $76 \pm 1\%$ peak pulmonary O₂ uptake ($\dot{V}_{O_{2,peak}}$), with skeletal muscle samples taken at rest and after 5 and 40 min of exercise. CaMKII expression and activities were examined by immunoblotting and in vitro kinase assays, respectively. There were no differences in maximal (+ Ca²⁺, CaM) CaMKII activity during exercise compared with rest. Autonomous (– Ca²⁺, CaM) CaMKII activity was $9 \pm 1\%$ of maximal at rest, remained unchanged at 5 min, and increased to $17 \pm 1\%$ ($P < 0.01$) at 40 min. CaMKII autophosphorylation at Thr²⁸⁷ was 50–70% higher during exercise, with no differences in CaMKII expression. The effect of maximal aerobic exercise on CaMKII was also examined ($n = 9$), with 0.7- to 1.5-fold increases in autonomous CaMKII activity, but no change in maximal CaMKII activity. CaMKIV was not detected in human skeletal muscle. In summary, exercise increases the activity of CaMKII in skeletal muscle, suggesting that it may have a role in regulating skeletal muscle function and metabolism during exercise in humans.

(Received 28 August 2003; accepted after revision 13 October 2003; first published online 17 October 2003)

Corresponding author M. Hargreaves: School of Health Sciences, Deakin University, Burwood, Australia 3125.
Email: mharg@deakin.edu.au

Calcium (Ca²⁺) is an important second messenger involved in regulating many cellular events (Berridge *et al.* 2000). In skeletal muscle, increases in intracellular Ca²⁺ due to release from the sarcoplasmic reticulum play a pivotal role in excitation–contraction coupling as well as other cellular events (Berchtold *et al.* 2000).

One action of the ubiquitously expressed Ca²⁺ sensor protein calmodulin (CaM) is to bind to and activate a family of Ser/Thr protein kinases known as the Ca²⁺–CaM-dependent protein kinases (CaMKs). One of these proteins is CaMKII, which is encoded by four homologous but distinct genes (α , β , γ and δ), and at least one gene product is expressed in all tissues including skeletal muscle (Tobimatsu & Fujisawa, 1989). CaMKII activity is detectable in skeletal muscle (Pelosi & Donella-Deana, 2000; Fluck *et al.* 2000b) and immunoblotting has revealed the presence of the γ and δ isozymes and a splice variant of the β isozyme designated β_M (Bayer *et al.* 1998; Sacchetto *et al.* 2000). A variant of the α isozyme is also expressed in skeletal muscle, but is non-functional as a kinase and is likely to be an anchoring protein (Bayer *et al.* 1996, 1998).

Unlike CaMKI and CaMKIV, CaMKII can be fully activated by Ca²⁺–CaM, independently of an upstream kinase (Hudmon & Schulman, 2002). A unique feature of the CaMKII is that upon activation by CaM binding, the heterotrimeric kinase undergoes intersubunit phosphorylation at a conserved amino acid residue (Thr286/7), making the kinase partially independent of Ca²⁺–CaM (Hudmon & Schulman, 2002). Thus, when a Ca²⁺ transient is over, the kinase retains heightened activity above basal (Hudmon & Schulman, 2002). Importantly, this characteristic is conserved in the CaMKII of skeletal muscle (Pelosi & Donella-Deana, 2000). Another important feature is that the activation of CaMKII is sensitive to the frequency of Ca²⁺ oscillations (De Koninck & Schulman, 1998).

Given that skeletal muscle CaMKII is not active at basal levels, but active at free Ca²⁺ concentrations seen during a twitch (Pelosi & Donella-Deana, 2000) it is likely that contractile activity activates skeletal muscle CaMKII. While there are studies examining the effect of contractile activity on CaMKII in skeletal muscle of rodents (Antipenko

et al. 1999; Fluck *et al.* 2000b), no studies have examined the effect of exercise on CaMKII in skeletal muscle of humans.

METHODS

Experimental protocol

Healthy, active but untrained, men ($n = 17$; 24 ± 5 years; body mass index (BMI) = 24 ± 2 kg m⁻²; mean \pm s.d.) were recruited for two separate studies. Written and verbal information about the purpose, nature, and potential risks relating to the experimental procedures was given to the subjects before they provided consent to participate. The protocol was reviewed and approved by the Deakin University Human Research Ethics Committee and conformed to the standards set by the Declaration of Helsinki (last modified in 2000). One to two weeks prior to testing, subjects completed an incremental exercise test to volitional exhaustion on an electromagnetically braked cycle ergometer (Lode, Groningen, The Netherlands) to determine their peak pulmonary O₂ uptake ($\dot{V}_{O_{2peak}}$), which averaged 51 ± 2 ml kg⁻¹ min⁻¹ (mean \pm s.e.m.). Expired air was analysed by O₂ and CO₂ analysers (AEI Technologies, Pittsburgh, PA, USA) and expired volume by a turbine ventilometer. The gas analysers were calibrated against gases of known composition prior to each test.

Subjects were asked to refrain from exercise as well as caffeine, nicotine and alcohol ingestion for 24 h prior to the study. Subjects were provided with a standardised meal (~80% CHO) for the evening prior to testing and reported to the laboratory in the morning after an overnight fast. In both studies, subjects rested for at least 20 min in the supine position before a muscle sample was obtained from the vastus lateralis by percutaneous needle biopsy under local anaesthesia and immediately frozen in liquid N₂. In one study subjects ($n = 8$) exercised for 40 min at $76 \pm 1\%$ $\dot{V}_{O_{2peak}}$ with biopsies taken at 5 and 40 min of exercise. In another study,

subjects ($n = 9$) performed bicycle exercise for 10 min at 50% $\dot{V}_{O_{2peak}}$, after which the resistance was increased to elicit a power output requiring 100% $\dot{V}_{O_{2peak}}$ and this was continued until volitional fatigue (3.5 ± 0.2 min) upon which a muscle sample was taken. During exercise, biopsy samples were taken and frozen within 20 s after the last contraction. Muscle samples were stored in liquid N₂ until analysis.

Analytical techniques

All chemicals were purchased from Sigma-Aldrich unless otherwise stated. To solubilise tissue protein, muscle samples were homogenised (Polytron X-100, Kinematica) in 1:12 (w/v) of ice-cold buffer (Buffer A) containing 50 mM Tris-HCl (pH 7.5), 250 mM sucrose, 1 mM EDTA, 1 mM EGTA, 1 mM phenylmethylsulphonic fluoride (PMSF), 1 mM dithiothreitol, 5 mM sodium fluoride, 5 mM sodium pyrophosphate, 10% glycerol, 1 mM benzamidine, and 5 μ l ml⁻¹ protease inhibitor cocktail. Samples were spun at 700 g for 5 min, and the supernatant was taken and supplemented with Buffer A containing Nonidet P-40 at a final concentration of 1% and mixed well at 4°C. The pellet was solubilised with an appropriate extraction buffer to yield a fraction of enriched nuclear proteins (McGee *et al.* 2003). Aliquots of both fractions were taken for total protein assay (Pierce BCA, Rockford, IL, USA) and the remaining lysate was stored at -80°C until analysis.

To detect CaMKII activity, samples were assayed *in vitro* as described previously (Fluck *et al.* 2000b), with minor modifications. To detect CaMKII activity in skeletal muscle lysates, 10–20 μ g of protein (5 μ l) was added to a preheated reaction mix composed of (final concentrations): 10 mM Hepes (pH 7.2), 5 mM MgCl₂, 1 mM EGTA, 0.1 mM sodium pyrophosphate, 0.1 mM ATP (0.2 Ci mmol⁻¹ 5'-[γ -³²P]ATP; Amersham Biosciences, Uppsala, Sweden), 25 μ M autocamtide-2 substrate peptide (Hanson *et al.* 1989; Upstate Biotech., Lake Placid, NY, USA) with (maximal) or without (autonomous) 1.2 mM CaCl₂ and 1.2 μ M calmodulin in a final reaction volume of 25 μ l. In preliminary experiments, autocamtide-2 related inhibitory peptide (AIP) was added to a final concentration of 10 μ M (Ishida *et al.* 1995) to confirm that the assay was specific for CaMKII. The reaction proceeded at 30°C for 2.5 min and was terminated by spotting 10 μ l of the reaction mix onto a P81 phosphocellulose filter paper (Whatman, Kent, UK). The reaction mix was absorbed for 2–3 s before washing in 75 mM phosphoric acid for at least 3×10 min. All reactions were run in duplicate (CV = $3.1 \pm 0.5\%$), and background reactions (without addition of peptide) were run for each sample and subtracted from maximal and autonomous counts. The incorporation of γ -³²P onto the peptide was measured by liquid scintillation counting (Wallac 1409, Turku, Finland), and enzyme activity was determined as described by Goueli *et al.* (2001). In order to directly measure CaMKII activity, CaMKII was immunopurified (IP) from muscle lysate protein. To do this 2 μ g of polyclonal CaMKII antibody (M-176, Santa Cruz Biotech., CA, USA) were incubated with 375 μ g of lysate protein in a final volume of 600 μ l with gentle mixing for 2 h at 4°C. Following this 40 μ l of 50% (v/v) of protein-A-sepharose (Amersham Biosciences) were added and further incubated with mixing for 2 h at 4°C. The bead-antibody-antigen complex was separated by centrifugation and washed three times with a buffer containing 10 mM Tris (pH 7.2), 1 mM sodium pyrophosphate and 1 mM EGTA, then resuspended with 55 μ l of buffer and aliquots were assayed for 10 min as described above. The activity of immunopurified CaMKII was ~30% of that of the lysate, mainly because of an inability to completely purify the kinase from the total amount of protein added (data not shown). The




Figure 1. CaMKII, but not CaMKIV, is expressed in human skeletal muscle

Solubilised protein from rat brain and human skeletal muscle tissue was subjected to immunoblotting procedures and probed using polyclonal CaMKII (A) and monoclonal CaMKIV (B) antibodies. Indicated are the various isoforms of CaMKII that are expressed.

assay time and protein added were within a linear range for lysate and IP assays (data not shown). Preliminary testing revealed that within-sample and between-assay CVs for the CaMKII assay were $4.5 \pm 0.7\%$ and $3.8 \pm 0.5\%$, respectively.

To provide a positive control for the assay, L6 skeletal myotubes were treated with Ca^{2+} ionophore A23187. All media solutions were purchased from Invitrogen. L6 myoblasts were grown in α MEM containing 10% horse serum and differentiated in α MEM containing 2% horse serum in standard culture conditions (37°C , 5% CO_2) until 80–90% confluent. L6 myotubes were serum starved overnight, and 1 h before experimentation serum-free media was replaced with Hank's Balanced Salt Solution (HBSS) containing 10 mM Hepes (pH 7.4), 1.26 mM CaCl_2 and 0.5 mM MgCl_2 . Cells ($n = 3$ dishes per treatment) were treated with $1 \mu\text{M}$ A23187 and control cells were treated with vehicle (0.1% ethanol) for 30 s. Media were aspirated and cells were lysed immediately and collected with Buffer A containing 1% Nonidet P-40 after 10 min on ice. Protein concentration was determined (range = $0.9\text{--}1.0 \text{ mg ml}^{-1}$) and CaMKII activity and expression were measured from lysates as

described above. There was a 3-fold increase (vehicle = $5.6 \pm 0.6\%$ maximal, A23187 = $16.0 \pm 1.0\%$ maximal; $P = 0.001$) in autonomous (with no change in maximal activity) CaMKII activity with ionophore treatment, as observed in other studies (MacNicol & Schulman, 1992).

To determine CaMKII expression and autophosphorylation, equal amounts of proteins in muscle lysate or IP samples were subjected to SDS-PAGE, transferred onto nitrocellulose membranes and blocked (5% skim milk in TBS-T, pH 7.4) for 1 h at room temperature. Membranes were washed and incubated with anti-CaMKII or anti-pThr²⁸⁶-CaMKII (Cell Signaling Tech., Beverly, MA, USA) antibodies (1:500) for 14–16 h at 4°C , after which they were washed. CaMKIV expression was detected using a monoclonal antibody (BD Biosciences, NJ, USA). Membranes were then incubated with peroxidase-conjugated secondary antibodies (Chemicon, Temecula, CA, USA; 1:5000 dilution) and washed thoroughly and proteins were visualised with chemiluminescence (Western Lightning, PerkinElmer, Boston, MA, USA) and light detection (Kodak Image Station 440CF).




Figure 2. Submaximal exercise increases autonomous, but not maximal, *in vitro* CaMKII activity in human skeletal muscle

Shown are the activities measured from tissue lysates (left column) and immunoprecipitates (IP, right column). Data are means \pm S.E.M. $n = 8$. * Significantly different from 0, $P < 0.01$.

Calculations and statistics analyses

Autonomous CaMKII activity was also expressed as a percentage of maximal CaMKII activity. Arbitrary units for protein abundance were expressed as a ratio of sample band intensity relative to an internal control band intensity. Statistical testing was done with *t* tests (MS Excel) or one-way ANOVA, with repeated measures with *post hoc* (Student-Newman-Keuls) testing being performed when differences were significant, as appropriate (GraphPad Prism, v.2.01). Data are expressed as means \pm S.E.M. and differences were considered to be significant when $P < 0.05$.

RESULTS

CaMKII is expressed in human skeletal muscle

Similar to animal studies (Bayer *et al.* 1998; Sacchetto *et al.* 2000), immunoblotting of human skeletal muscle for CaMKII yielded a band at 72 kDa corresponding to the β_M isozyme, and a strong band at approximately 55 kDa which is likely to be either or both the δ and γ isozymes (Fig. 1A). Despite being able to detect CaMKIV in rat brain, no signal was detected for CaMKIV in human skeletal muscle (Fig. 1B). In resting muscle, Ca^{2+} -CaM-stimulated activity was 8- to 10-fold higher than activity measured without Ca^{2+} and CaM as has been observed in rat skeletal muscle (Fluck *et al.* 2000a). In preliminary experiments, maximal and autonomous activity were inhibited by 75–90% when 10 μM AIP was added to the reaction, indicating that the predominant kinase contributing to phosphate transfer in

the reaction is likely to be CaMKII. Taken together, these data suggest that CaMKII is expressed in human skeletal muscle.

Skeletal muscle CaMKII is activated by exercise

As can be seen in Fig. 2, autonomous CaMKII activity during submaximal, high-intensity exercise was not higher at 5 min, but was $74 \pm 24\%$ higher at 40 min when compared with basal activity. There was a slight decrease in maximal CaMKII activity, but this was not statistically significant. To examine whether this decrease was due to movement of the CaMKII to the nuclei, immunoblotting was performed on the lysates from a fraction enriched in nuclei (data not shown). No differences in the abundance




Figure 3. Submaximal exercise increases CaMKII autophosphorylation at Thr²⁸⁷

Solubilised proteins from crude skeletal muscle tissue extracts were subjected to immunoblotting procedures and probed using a polyclonal pT²⁸⁷-CaMKII antibody. Data are means \pm S.E.M. $n = 8$. * Significantly different from 0, $P < 0.05$.




Figure 4. Maximal aerobic exercise (3.5 ± 0.2 min) increases autonomous, but not maximal, *in vitro* CaMKII activity in human skeletal muscle

Shown are the activities measured from tissue lysates (left column) and immunoprecipitates (IP, right column). Data are means \pm S.E.M. $n = 9$ (lysate), $n = 6$ (IP). * Significantly different from Basal, $P < 0.05$.

of 55 kDa CaMKII abundance between time points in this fraction were seen (the 72 kDa band was barely detectable). In addition, there were no differences in the abundance of CaMKII in the crude lysate preparations used for activity measurements (data not shown). However, phosphorylation of CaMKII- δ/γ at Thr²⁸⁷ was $67 \pm 12\%$ and $52 \pm 14\%$ higher at 5 and 40 min, respectively ($P < 0.01$), while no differences in CaMKII- β_M phosphorylation were seen, when compared with the basal sample (Fig. 3). As can be seen in Fig. 4, autonomous CaMKII activity was 0.7- to 1.5-fold higher after 3–5 min of maximal aerobic exercise, but there were no differences in maximal CaMKII activity. Taken together, these data suggest that CaMKII is activated in contracting skeletal muscle during exercise in humans.

DISCUSSION

This is the first study to directly demonstrate activation of CaMKII in contracting human skeletal muscle when measured immediately post exercise. This finding is in agreement with a study of isolated mouse skeletal muscle fibres that presented indirect evidence that CaMKII activity is increased by repeated contractions (Tavi *et al.* 2003). Furthermore, Fluck *et al.* (2000b) have demonstrated increases in autonomous CaMKII activity in overloaded avian muscle and in rodent skeletal muscle after 14 days of voluntary wheel running. In the present study, there were no significant changes in maximal *in vitro* CaMKII activity, while autonomous CaMKII activity increased from approximately 9–11% of maximal in basal samples to 16–25% with exercise. This appears to be very modest activation considering that autonomous activity can reach up to 50–60% of maximal in an *in vitro* preparation of rabbit skeletal muscle (Pelosi & Donella-Deana, 2000). However, it has been observed that the generation of autonomous activity through mobilisation of intracellular Ca²⁺ in cells is consistently lower than that which can be generated by incubation of enzyme with Ca²⁺ *in vitro* (Hudmon & Schulman, 2002). When comparing the two different exercise intensities, it appears that there is generally a larger increase in autonomous activity with maximal aerobic exercise (~1-fold increase) when compared with high-intensity submaximal exercise (~0.7-fold increase). This could be the result of a greater proportion of active muscle fibres or greater Ca²⁺ levels in individual fibres with the higher exercise intensity. Regardless, the effect of exercise intensity was not directly examined and warrants further investigation.

The mechanism for increased autonomous activity of CaMKII appears to be related to increased phosphorylation at Thr²⁸⁷. In the present study, a 50–70% increase in Thr²⁸⁷ phosphorylation of CaMKII in contracting muscle during submaximal exercise was observed. Similarly, a preliminary report demonstrated 2-fold higher CaMKII auto-phosphorylation with tetanic stimulation of rat hindlimb

muscle (Wright *et al.* 2003). The increase in autonomous activity is likely to be caused by a direct effect of Ca²⁺, whereby the generation of transient Ca²⁺ 'spikes' by depolarisation induces CaM binding, and subsequent activation and autophosphorylation, as has been observed in a cell-free system (De Koninck & Schulman, 1998) and intact neurons (Eshete & Fields, 2001). The functional consequence of autophosphorylation is believed to be maintenance of activity between Ca²⁺ transients, thereby allowing persistent phosphorylation of downstream substrates during repeated stimulation (Hudmon & Schulman, 2002).

While CaMKIV is expressed in murine skeletal muscle (J. T. Treebak, A. J. Rose & M. Hargreaves, unpublished observations), it was not detected in human skeletal muscle in the present study. Although immunopurified maximal *in vitro* CaMKIV activity was detected in human skeletal muscle, albeit at levels much lower than CaMKII, it was not influenced by exercise (data not shown). CaMKI is also expressed in rat skeletal muscle (Picciotto *et al.* 1993), and is expressed at the mRNA level in human skeletal muscle (S. L. McGee, A. J. Rose & M. Hargreaves, unpublished observations). Further study is needed to reveal the effect of contractions on skeletal muscle CaMKI.

Although no functional effects of CaMKII activation were examined in the present study, there is evidence from other studies that CaMKII may be involved in modification of skeletal muscle function with exercise, including the regulation of Ca²⁺ homeostasis, metabolism and gene expression. A recent study revealed that injection of a specific CaMKII inhibitor into intact mouse fast-twitch skeletal muscle fibres resulted in a decrease in the force production in response to a tetanic electrical stimulus which was associated with a blunted increase in Ca²⁺ (Tavi *et al.* 2003). Given that CaMKII inhibition had no effect on sarcoplasmic reticulum (SR) Ca²⁺ uptake or the force–Ca²⁺ relationship, it was concluded that CaMKII activation during exercise is likely to affect SR Ca²⁺ release by phosphorylating and further activating the SR Ca²⁺ release channels during tetanic stimulation (Tavi *et al.* 2003). Indeed, there is evidence in rabbit skeletal muscle that CaMKII inhibition can blunt the activation of the Ca²⁺ release channel (Dulhunty *et al.* 2001). There is also evidence that CaMKII can phosphorylate the SR Ca²⁺ pumps in rabbit slow-twitch, but not fast-twitch, skeletal muscle and accelerate SR Ca²⁺ uptake (Hawkins *et al.* 1994). However, while Ca²⁺ pumps and channels appear to be substrates of CaMKII in animal skeletal muscle, the only identified substrate of endogenous CaMKII (other than itself) in human skeletal muscle is phospholamban (PLB; Margreth *et al.* 2000). Phosphorylation of PLB by CaMKII is believed to relieve the inhibition of the SR Ca²⁺ pumps by disrupting the physical interaction between the Ca²⁺ pumps and PLB (for review see Simmerman & Jones, 1998). Thus, in human muscle, CaMKII may regulate Ca²⁺ homeostasis

during contraction by altering SR Ca²⁺ uptake through PLB-Ca²⁺ pump phosphorylation, although no studies have directly investigated this.

Several studies suggest that Ca²⁺ spikes may be involved in the stimulation of glucose transport during muscle contraction (Richter *et al.* 2003). There is evidence that CaMKII inhibition can block hypoxia- and insulin-stimulated glucose transport in skeletal muscle (Brozinick *et al.* 1999), and a preliminary report has demonstrated a 50% inhibition of glucose transport with tetanic stimulation of rat hindlimb muscle (Wright *et al.* 2003). There are several lines of evidence that increases in Ca²⁺ may mediate some adaptive responses to repeated exercise (Berchtold *et al.* 2000) and that CaMKs are potentially involved in this response (Fluck *et al.* 2000b; Ojuka *et al.* 2002). Indeed, CaMKII can phosphorylate transcription factors such as cAMP response element binding protein (Sheng *et al.* 1991) and serum response factor (Fluck *et al.* 2000a). Thus, the activation of skeletal muscle CaMKII during exercise describes a potential mechanism by which muscle contractions increase glucose transport and gene transcription in skeletal muscle. Further studies are needed to confirm the functional significance of CaMKII activation.

In summary, exercise increases the autonomous, but not the maximal, activity of CaMKII in skeletal muscle of humans. The mechanism for increased autonomous CaMKII activity is related to higher CaMKII autophosphorylation at Thr²⁸⁷.

REFERENCES

- Antipenko A, Frias JA, Parra J, Cadefau JA & Cusso R (1999). Effect of chronic electrostimulation of rabbit skeletal muscle on calmodulin level and protein kinase activity. *Int J Biochem Cell Biol* **31**, 303–310.
- Bayer KU, Harbers K & Schulman H (1998). α KAP is an anchoring protein for a novel CaM kinase II isoform in skeletal muscle. *EMBO J* **17**, 5598–5605.
- Bayer KU, Lohler J & Harbers K (1996). An alternative, nonkinase product of the brain-specifically expressed Ca²⁺/calmodulin-dependent kinase II α isoform gene in skeletal muscle. *Mol Cell Biol* **16**, 29–36.
- Berchtold MW, Brinkmeier H & Muntener M (2000). Calcium ion in skeletal muscle: its crucial role for muscle function, plasticity, and disease. *Physiol Rev* **80**, 1215–1265.
- Berridge MJ, Lipp P & Bootman MD (2000). The versatility and universality of calcium signalling. *Nat Rev Mol Cell Biol* **1**, 11–21.
- Brozinick JT Jr, Reynolds TH, Dean D, Cartee G & Cushman SW (1999). 1-[N, O-bis-(5-isoquinolinesulphonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazine (KN-62), an inhibitor of calcium-dependent camodulin protein kinase II, inhibits both insulin- and hypoxia-stimulated glucose transport in skeletal muscle. *Biochem J* **339**, 533–540.
- De Koninck P & Schulman H (1998). Sensitivity of CaM kinase II to the frequency of Ca²⁺ oscillations. *Science* **279**, 227–230.
- Dulhunty AF, Laver D, Curtis SM, Pace S, Haarmann C & Gallant EM (2001). Characteristics of irreversible ATP activation suggest that native skeletal ryanodine receptors can be phosphorylated via an endogenous CaMKII. *Biophys J* **81**, 3240–3252.
- Eshete F & Fields RD (2001). Spike frequency decoding and autonomous activation of Ca²⁺-calmodulin-dependent protein kinase II in dorsal root ganglion neurons. *J Neurosci* **21**, 6694–6705.
- Fluck M, Booth FW & Waxham MN (2000a). Skeletal muscle CaMKII enriches in nuclei and phosphorylates myogenic factor SRF at multiple sites. *Biochem Biophys Res Commun* **270**, 488–494.
- Fluck M, Waxham MN, Hamilton MT & Booth FW (2000b). Skeletal muscle Ca²⁺-independent kinase activity increases during either hypertrophy or running. *J Appl Physiol* **88**, 352–358.
- Goueli SA, Hsiao K & Goueli BS (2001). Assaying activity of individual protein kinases in crude tissue or cellular extracts. *Methods Enzymol* **333**, 16–27.
- Hanson PI, Kapiloff MS, Lou LL, Rosenfeld MG & Schulman H (1989). Expression of a multifunctional Ca²⁺/calmodulin-dependent protein kinase and mutational analysis of its autoregulation. *Neuron* **3**, 59–70.
- Hawkins C, Xu A & Narayanan N (1994). Sarcoplasmic reticulum calcium pump in cardiac and slow twitch skeletal muscle but not fast twitch skeletal muscle undergoes phosphorylation by endogenous and exogenous Ca²⁺/calmodulin-dependent protein kinase. Characterization of optimal conditions for calcium pump phosphorylation. *J Biol Chem* **269**, 31198–31206.
- Hudmon A & Schulman H (2002). Structure–function of the multifunctional Ca²⁺/calmodulin-dependent protein kinase II. *Biochem J* **364**, 593–611.
- Ishida A, Kameshita I, Okuno S, Kitani T & Fujisawa H (1995). A novel highly specific and potent inhibitor of calmodulin-dependent protein kinase II. *Biochem Biophys Res Commun* **212**, 806–812.
- McGee SL, Howlett KF, Starkie RL, Cameron-Smith D, Kemp BE & Hargreaves M (2003). Exercise increases nuclear AMPK α 2 in human skeletal muscle. *Diabetes* **2**, 926–928.
- MacNicol M & Schulman H (1992). Cross-talk between protein kinase C and multifunctional Ca²⁺/calmodulin-dependent protein kinase. *J Biol Chem* **267**, 12197–12201.
- Margreth A, Pallanca A & Damiani E (2000). Calmodulin kinase-mediated phosphorylation of phospholamban in skeletal muscle sarcoplasmic reticulum. A critical reappraisal of the state of the problem in the light of new findings with normal and diseased muscle. *Basic Appl Myol* **10**, 151–157.
- Ojuka EO, Jones TE, Nolte LA, Chen M, Wamhoff BR, Sturek M & Holloszy JO (2002). Regulation of GLUT4 biogenesis in muscle: evidence for involvement of AMPK and Ca²⁺. *Am J Physiol Endocrinol Metab* **282**, E1008–1013.
- Pelosi M & Donella-Deana A (2000). Localization, purification, and characterization of the rabbit sarcoplasmic reticulum associated calmodulin-dependent protein kinase. *Biochemistry (Mosc)* **65**, 259–268.
- Piccioletto MR, Czernik AJ & Nairn AC (1993). Calcium/calmodulin-dependent protein kinase I. cDNA cloning and identification of autophosphorylation site. *J Biol Chem* **268**, 26512–26521.

- Richter EA, Nielsen JN, Jorgensen SB, Frosig C, Wojtaszewski JF (2003). Signalling to glucose transport in skeletal muscle during exercise. *Acta Physiol Scand* **178**, 329–335.
- Sacchetto R, Damiani E, Pallanca A, Margreth A (2000). Coordinate expression of Ca²⁺-ATPase slow-twitch isoform and of beta calmodulin-dependent protein kinase in phospholamban-deficient sarcoplasmic reticulum of rabbit masseter muscle. *FEBS Lett* **481**, 255–260.
- Sheng M, Thompson MA & Greenberg ME (1991). CREB: a Ca²⁺-regulated transcription factor phosphorylated by calmodulin-dependent kinases. *Science* **252**, 1427–1430.
- Simmerman HK & Jones LR (1998). Phospholamban: protein structure, mechanism of action, and role in cardiac function. *Physiol Rev* **78**, 921–947.
- Tavi P, Allen DG, Niemela P, Vuolteenaho M & Westerblad H (2003). Calmodulin kinase modulates Ca²⁺ release in mouse skeletal muscle. *J Physiol* **551**, 5–12.
- Tobimatsu T & Fujisawa H (1989). Tissue-specific expression of four types of rat calmodulin-dependent protein kinase II mRNAs. *J Biol Chem* **264**, 17907–17912.
- Wright DC, Holloszy JO & Han DG (2003). The role of calmodulin kinase (CAMK) in calcium and contraction induced muscle glucose transport. *Diabetes* **52**, A12.

Acknowledgements

The technical assistance of Dr Andrew Garnham, Ms Janelle Mollica, Dr George Kraniou and Mr Sean McGee is gratefully acknowledged. The authors also acknowledge the scientific input of Dr Belinda Michell and Professor Bruce Kemp in the development of assay procedures.